Schwedhelm Shelly S, Wadman Michael C
1Nebraska Biocontainment Unit, Nebraska Medicine, Omaha, NE USA.
2Department of Emergency Medicine, Nebraska Medicine, University of Nebraska Medical Center, Omaha, NE USA.
Curr Treat Options Infect Dis. 2016;8(4):215-227. doi: 10.1007/s40506-016-0099-z. Epub 2016 Nov 8.
Patients presenting with epidemiological risk factors for Ebola virus disease (EVD) and symptoms consistent with the disease require screening with a molecular assay. If the initial test is negative, but the patient has been symptomatic for less than 3 days, a follow-up test is required to reliably exclude the disease. During this time, persons under investigation (PUI) for EVD may have illnesses other than EVD that require further evaluation and management and well-defined processes are essential to the delivery of consistent, high-quality care for these patients while preserving the safety of healthcare providers.
出现埃博拉病毒病（EVD）流行病学风险因素且症状与该病相符的患者需要通过分子检测进行筛查。如果初始检测为阴性，但患者出现症状的时间少于3天，则需要进行后续检测以可靠地排除该病。在此期间，埃博拉病毒病疑似患者（PUI）可能患有除埃博拉病毒病之外的其他疾病，需要进一步评估和处理，明确的流程对于为这些患者提供一致、高质量的护理同时保障医护人员的安全至关重要。
